Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2012 by Echosense Ltd.
Clalit Health Services, Haifa and West Galilee
Information provided by (Responsible Party):
Echosense Ltd. Identifier:
First received: May 25, 2011
Last updated: August 2, 2014
Last verified: June 2012

This is a study that seeks to characterize data obtained from patients with a variety of lung diseases using ultrasound signals obtained from the lung tissue. A standard ultrasound instrument in the doppler mode (not the imaging mode used in examination of pregnant women for instance) is placed on the chest wall and the unique software the investigators have developed analyzes the signal reflected back from within the lung. On the basis of pilot studies performed previously the investigators expect to receive different signals from different diseases. The investigators seek to further characterize these signals to enable accurate diagnosis of different lung diseases using our technology.

Lung Disease, Chronic Obstructive
Lung Disease, Interstitial
Hypertension, Pulmonary

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Detection and Characterization of Cardio-Pulmonary Patho-Physiological States and Diseases by Transthoracic Parametric Doppler (TPD)

Resource links provided by NLM:

Further study details as provided by Echosense Ltd.:

Primary Outcome Measures:
  • Diagnose specific pattern of the LDS signals as Power and Velocity in pulmonary diseases in comparison to controls. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 550
Study Start Date: August 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients referred to a large hospital-affiliated community lung clinic.



Age 18 years or older Patients who are clinically suspected of having pulmonary, cardiac or Cardio-pulmonary disease preferably any one or more of the conditions listed below:

  • Patients with CHF
  • Patients with pulmonary hypertension with documented right heart catheterization data
  • Patients with COPD in two subgroups:

    • Emphysema, (evidence of emphysema on High Resolution Computed Tomography, (HRCT) and airflow limitation of GOLD II severity who have had Carbon Monoxide Diffusing capacity, (DLCO) and Residual Volume(RV) measured, or patients without HRCT with measurements of lung volumes and diffusing capacity with Total Lung Capacity (TLC) ≥1.0 predicted, RV/TLC ≥0.4, DLCO ≤ 0.7 predicted.
    • Chronic Bronchitis (No evidence of Emphysema on HRCT and/or no evidence of air-trapping or reduced DLCO.)
  • Patients with asthma according to ATS/ERS definition,
  • Patients with interstitial lung disease (ILD) of any etiology including sarcoidosis diagnosed by HRCT in sub groups as follows:

    • Mild ILD (TLC 0.71-0.79 predicted, DLCO ≥ 0.71 predicted)
    • Moderate and severe ILD (TLC ≤ 0.7 predicted, DLCO ≤ 0.7 predicted)
  • Signed informed consent.
  • Patients with sarcoidosis without evidence of parenchymal lung disease defined as normal DLCO and/or HRCT.


  • Patients unable to cooperate.
  • Inability to assume a semi-reclining or supine position
  • Patients with severe chest wall deformity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01361139

Contact: Daniel Weiler, MD +972-54-5322422
Contact: Uzi Milmann, MD +972-50-6261360

Regional Clinic for Pulmonary Disease, Haifa and Western Galilee, Clalit Health Services Not yet recruiting
Haifa, Israel, 35053
Principal Investigator: Uzi Milman, MD         
Sub-Investigator: Arie Brik         
Sub-Investigator: Assaf Jacobi, MD         
Sub-Investigator: Svetlana Pojurovsky, MD         
Sub-Investigator: Michal Shteinberg, MD         
Sub-Investigator: DANIEL WEILER, MD         
Regional Pulmonary Clinic, Clalit Health Services Recruiting
Haifa, Israel, 3505331
Contact: DANIEL WEILER, MD    +972545322422   
Contact: RAMI UNTERMAN, ISRAEL    +972527077224   
Sub-Investigator: DANIEL WEILER, MD         
Principal Investigator: UZI MILMAN, MD         
Sponsors and Collaborators
Echosense Ltd.
Clalit Health Services, Haifa and West Galilee
Study Director: Daniel Weiler, MD Echosense Ltd.
Principal Investigator: Uzi Milman, MD Clalit Health Services
  More Information

No publications provided

Responsible Party: Echosense Ltd. Identifier: NCT01361139     History of Changes
Other Study ID Numbers: DOP09
Study First Received: May 25, 2011
Last Updated: August 2, 2014
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Echosense Ltd.:
Chronic obstructive lung disease
Interstitial lung disease
Pulmonary hypertension
Lung disease diagnosis

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Interstitial
Chronic Disease
Hypertension, Pulmonary
Cardiovascular Diseases
Disease Attributes
Lymphatic Diseases
Lymphoproliferative Disorders
Pathologic Processes
Respiratory Tract Diseases
Vascular Diseases processed this record on November 24, 2014